Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New targeted radiation therapy shows promise for Hard-to-Treat tumors

NCT ID NCT05153772

First seen May 02, 2026 · Last updated May 24, 2026 · Updated 5 times

Summary

This study tests a new radioactive drug, 212Pb-DOTAMTATE, in 69 adults with neuroendocrine tumors that have spread or cannot be removed. The drug targets tumor cells and delivers radiation directly to them. The goal is to see if it shrinks tumors and to check for side effects. Participants include those who have or have not had a similar radiation therapy before.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Excel Diagnostics and Nuclear Oncology Center

    Houston, Texas, 77042, United States

  • Louisiana State University (LSU) Health Sciences Center - New Orleans

    Metairie, Louisiana, 70006, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Rocky Mountain Cancer Center

    Denver, Colorado, 80218, United States

Conditions

Explore the condition pages connected to this study.